Omidubicel

Summary

Omidubicel (CHEMBL4298190) is an approved cell; indicated across 2 conditions including lymphoid neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Cell
• Indications: 2 conditions
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298190
Name	Omidubicel
Type	Cell
Max phase	4

Also known as: Cultured fraction, CF, Nicord, Omidubicel, Omidubicel component of omisirge, cultured fraction, OMIDUBICEL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
lymphoid neoplasm	4	MONDO:0005157	EFO:0001642

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04260698	PHASE3	COMPLETED	Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
NCT01590628	PHASE1/PHASE2	COMPLETED	Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).